Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgments
Executive Summary
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
You may also be interested in...
FDA Patent Listing Review System Suggested By Paxil Appeals Court
An FDA system for review of patents for "Orange Book" listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4
GPhA Eyes Trade Deals As Vehicle For U.S. Waxman/Hatch Reform
The Generic Pharmaceutical Association could use negotiations for free trade agreements as an opportunity to enact changes in U.S. Waxman/Hatch provisions, consultant Fabiana Jorge (MFJ International) told the GPhA annual meeting
FDA Patent Listing Review System Suggested By Paxil Appeals Court
An FDA system for review of patents for "Orange Book" listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4